Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--European Medicines Agency Validates Bristol Myers Squibb's Applications for Opdivo+ Yervoy and Opdivo + Chemotherapy as First-Line Treatments for....

EMA Validates Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

AbbVie

Biogen

General Motors

Kroger

Merck

Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and added positions in Kroger Inc (NYSE: KR) and Aon Plc (NYSE: AON), in the second quarter, regulatory filings revealed on Monday. What Happened: The Omaha, Nebraska-based conglomerate disclosed it has trimmed its position in the legacy automaker GM by 10.44%, as it shed 60 million shares, lowering its total stake in GM to $3.55 billion at the end of June, compared with $3.85 billion a quarter ago.

Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2

Axalta Coating Systems

Chevron

Liberty Global Ltd

Marsh & McLennan

Organon & Co

U.S. Bancorp

Berkshire Hathaway CEO Warren Buffett and his team were bears yet again in Q2 2021, hacking away at a large number of positions while only adding to a handful.

11 Stocks Warren Buffett Is Selling (And 3 He's Buying)

Warren Buffett's Berkshire Hathaway Inc said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co spinoff, Organon & Co.

Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen

Allstate

Anthem

Best Buy

Goldman Sachs

Huntington Ingalls Industries

L3Harris

Medifast

Morgan Stanley

SPDR S&P 500 ETF Trust

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration.

10 Dividend Growth Stocks For August 2021

BGC Partners

Lincoln National

Mercer International

Benjamin Graham is known for developing a fairly complex set of rules and formulas to determine a stock's intrinsic value. In his final year, Graham offered a much simpler means of finding value, but these simple value comparison tools are often overlooked by many investors.

Value Stock Selections: A Simpler Benjamin Graham

Mirati Therapeutics

Sanofi

The next few months are critical for these biotech stocks which could witness a massive increase in their stock prices this year The post 3 Best Biotech Stocks To Buy for Upcoming Catalysts appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

3 Best Biotech Stocks To Buy for Upcoming Catalysts

PRINCETON, N.J.--(BUSINESS WIRE)---- $bmy #BristolMyers--BMS and Five Leading Historically Black Colleges and Universities Launch Tomorrow's Innovators to Create Custom Biopharma Educational Programming and

Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow's Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry

Abbott Labs

Cigna

Johnson & Johnson

Medtronic

PIMCO Corporate & Income Opportunity Fund

Cohen & Steers Reit And Preferred Income Fund Inc

abrdn Life Sciences Investors 

Thermo Fisher Scientific

UnitedHealth Group

A monthly income stream provides a lot of flexibility for the income investor. Monthly dividends makes DCA work even better.

3 Big Dividends, Paying Monthly, For Your Retirement Basea

Air Products and Chemicals

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

Brookfield Infrastructure

Enterprise Products Partners

Innovative Industrial Properties

PepsiCo

Pfizer

All of them offer attractive dividends and solid growth prospects, too.

Here Are the 12 Best Dividend Stocks I Own Right Now

Duke Energy

Annaly Capital

These income stocks will put inflation in its place and cash in your pockets.

4 Perfect Dividend Stocks That'll Help You Crush Inflation

Trefis expects Bristol-Myers Squibb's (NYSE:BMY) Cardiovascular Drugs Revenue to rise from $9.2 billion in 2020 to $11.4 billion in 2021 and to $12.6 billion in 2022.

Forecast Of The Day: Bristol-Myers Squibb's Cardiovascular Drugs Revenue

Takeda Pharmaceutical

It has become the proverbial broken record. Every time it seems like yields on government securities will start trending higher, they roll over again.

4 Big Pharma Dividend Stocks to Buy as Yields Near 2021 Lows

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland

Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland

The European Commission (EC) has approved Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) as adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer. The approval covers patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).

Bristol Myers' Opdivo Scores European Approval As Adjuvant Treatment For Gastric Cancer

Citizens Financial Group

Marathon Petroleum

Raytheon Technologies

As the aging bull market presses ahead, it is pretty easy to see there has been a big rotation out of growth and momentum stocks and into value and cyclical companies.

6 Goldman Sachs Top Stock Picks Also Pay Big-Time Dependable Dividends

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for Opdivo As Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients....

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy

Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.

Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow

Bristol Myers Squibb (BMY) CEO Giovanni Caforio on Q2 2021 Results - Earnings Call Transcript

Shares of Bristol Myers Squibb rose early Wednesday, after the company reported earnings that just beat Wall Street expectations.

Bristol Myers Squibb Stock Rises After Modest Earnings Beat

Bristol Myers (BMY) delivered earnings and revenue surprises of 2.66% and 4.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates

Bristol Myers Squibb & Co (NYSE: BMY) posted Q2 revenues of $11.7 billion, an increase of 16%, or 13%, when adjusted for foreign exchange, slightly above the consensus estimate of $11.3 billion.  Sales in the same period a year ago were negatively impacted by approximately $350 million of COVID-19-related channel inventory work downs.

Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS Guidance

Shares of Bristol-Myers Squibb (NYSE:BMY) decreased 0.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 18.40% over the past year to $1.93, which beat the estimate of $1.91.

Recap: Bristol-Myers Squibb Q2 Earnings

Bristol Myers Squibb Co. said Wednesday it swung to a profit of $1.055 billion, or 47 cents a share, in the second quarter, after a loss of $85 million, or 4 cents a share, in the year-earlier period. Adjusted per-share earnings came to $1.93, ahead of the $1.89 FactSet consensus.

Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth

News for Bristol-Myers Stock (BMY)